SLC4A5: A Potential Drug Target Or Biomarker (G57835)

Target Name: SLC4A5

NCBI ID: G57835

SLC4A5

SLC4A5: A Potential Drug Target Or Biomarker

SLC4A5 (SLC4A5 variant a) is a gene that has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and psychiatric disorders. SLC4A5 is a member of the SLC4A family, which is known for its role in transporting various molecules across cell membranes. The SLC4A5 gene has four splice variants, including variant a, which is the most abundant.

The SLC4A5 gene is located on chromosome 12q34 and has been implicated in various health conditions. Studies have shown that individuals with certain genetic variations in the SLC4A5 gene are at increased risk for developing certain diseases, including cancer, neurodegenerative diseases, and psychiatric disorders. For example, individuals with the SLC4A5A variation are at increased risk for appendicitis, a common digestive disease, and may also be more likely to develop certain cancers, such as colon cancer.

In addition to its association with various diseases, SLC4A5 has also been shown to play a role in several cellular processes that are important for normal cell function. For example, SLC4A5 is involved in the transport of chloride ions across the cell membrane, which is important for maintaining the proper levels of ion balance in the body. SLC4A5 is also involved in the regulation of the production of various signaling molecules, including neurotransmitters, which are important for communication between cells.

Given its involvement in multiple cellular processes, SLC4A5 has potential as a drug target or biomarker. Researchers are interested in using SLC4A5 as a target for small molecules or antibodies that can modulate its activity and trigger various cellular responses. For example, SLC4A5 has been shown to be involved in the regulation of pain perception, which makes it an attractive target for pain medications. SLC4A5 has also been shown to be involved in the regulation of anxiety and depression, which makes it an attractive target for compounds that can alleviate these symptoms.

In addition to its potential as a drug target or biomarker, SLC4A5 is also of interest as a potential biomarker for certain diseases. The SLC4A5 gene has been shown to be expressed in various tissues and cells, including brain, spinal cord, and pancreatic cancer cells. This suggests that SLC4A5 could be a useful biomarker for these diseases, as it may be possible to detect changes in its expression levels in response to certain treatments or therapies.

Overall, SLC4A5 is a gene that has significant potential as a drug target or biomarker. Its involvement in various cellular processes and its association with multiple diseases make it an attractive target for small molecules or antibodies that can modulate its activity. Additionally, SLC4A5 has the potential to serve as a biomarker for various diseases, as its expression has been shown in various tissues and cells. Further research is needed to fully understand the potential of SLC4A5 as a drug target or biomarker.

Protein Name: Solute Carrier Family 4 Member 5

Functions: Mediates sodium- and bicarbonate-dependent electrogenic sodium bicarbonate cotransport, with a Na(+):HCO3(-) stoichiometry varying from 1:2 to 1:3

The "SLC4A5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC4A5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets